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Filarial Antigenemia and Loa loa Night Blood Microfilaremia in an Area Without
Bancroftian Filariasis in the Democratic Republic of Congo
Didier K. Bakajika, Maurice M. Nigo, Jean Pierre Lotsima, Germain A. Masikini, Kerstin Fischer, Melanie M. Lloyd,
Gary J. Weil, and Peter U. Fischer*
Programme National de Lutte contre L’Onchocercose, Kinshasa, Democratic Republic of Congo; Centre de Recherche en Maladies
Tropicales de l’Ituri, Ituri, Congo, Democratic Republic of Congo; Infectious Diseases Division, Department of Internal Medicine,
Washington University School of Medicine, St. Louis, Missouri
Abstract. Implementation of mass drug administration for lymphatic filariasis (LF) has been delayed in central
Africa because of incomplete mapping and coendemic loiasis. We mapped two regions in eastern Democratic Republic
of Congo that were suspected to have LF. Night blood samples were collected from 2,724 subjects in 30 villages. Filarial
antigenemia rates by card test exceeded 1% in 28 villages (range = 0–14%). Prevalence rates for large sheathed
microfilariae (Mf) ranged from 4% to 40%; Mansonella perstans rates ranged from 22% to 98%. Large Mf were
exclusively Loa loa by microscopy, and only 1 of 337 samples tested by quantitative polymerase chain reaction (qPCR)
was positive forWuchereria bancroftiDNA. Filarial antigen positivity was strongly associated with high L. loaMf counts.
Periodicity studies revealed atypical patterns, with no significant diurnal periodicity in some individuals. Thus, methods
routinely used for LF mapping may not be reliable in areas in central Africa that are highly endemic for loiasis.
INTRODUCTION
Lymphatic filariasis (LF) affects some 120 million people in
73 countries, and approximately 1.3 billion people are at risk of
becoming infected with the nematode parasites (Wuchereria
bancrofti and Brugia species) that cause this disease.1 The
Global Program to Eliminate Lymphatic Filariasis (GPELF)
is using mass drug administration (MDA) to reduce filarial
infection rates below those required for sustained transmission
with the goal of permanently eliminating LF in all endemic
countries by the year 2020. The progress of GPELF is variable:
some countries have already approached the elimination tar-
get, whereas others have not even started withMDA. Accurate
mapping of the distribution of LF is a crucial first step for LF
elimination programs. This is especially important for regions
with loiasis, because ivermectin used in LF elimination pro-
grams can cause serious adverse events (including death) in
persons with heavy Loa loa infections. Two tests that are
widely used for mapping LF are microfilaria (Mf) detection
(by microscopic examination of stained thick smears prepared
with blood collected at night) and detection of filarial anti-
genemia (immunological detection of soluble W. bancrofti
antigens in peripheral blood) by immunochromatographic
card test (ICT). Because W. bancrofti Mf in Africa exhibit
nocturnal periodicity and because L. loa Mf exhibit diurnal
periodicity, large sheathed Mf in night blood are generally
assumed to beW. bancrofti, and Mf present in blood collected
during the day are assumed to be L. loa.2 Mansonella perstans
is a third filarial species that infects humans in many areas of
Africa, but M. perstans Mf can easily be distinguished from
those of L. loa and W. bancrofti based on their smaller size
and lack of a sheath.
The circulating W. bancrofti antigen that is detected by the
ICT card test is present in blood collected during the day or
night. For convenience reasons, the test is often performed
with blood samples collected during the day. Furthermore,
this test has be extensively evaluated and used in many parts
of the world for mapping and monitoring LF elimination pro-
grams. However, the ICT card test has not been widely used
in the past in central Africa, because large-scale LF elimina-
tion programs have not been started in most countries in this
region. This paper shows that tests that are routinely used to
map LF may not provide accurate results in areas of central
Africa that are highly endemic for loiasis.
MATERIALS ANDMETHODS
Study area. In total, 14 villages in the Ituri region (Mambasa
Territory) and 16 villages in the Haut Uele region (Watsa
Territory) of the Orientale Province in the eastern Demo-
cratic Republic of Congo (DRC) (Figure 1 and Supplemental
Table 1) were screened for Mf and filarial antigenemia. Most
villages were located in remote forested areas east of the
Okapi game reserve. The surveys were conducted in July of
2011 and January of 2013. No community-directed treatment
with ivermectin had been performed in the study areas before
these surveys. Historically the Ituri region has been reported to
be endemic for L. loa,W. bancrofti, andM. perstans (with Mf in
the blood) as well as Onchocerca volvulus and M. streptocerca
(with Mf in skin).3 More recent rapid epidemiological mapping
of onchocerciasis indicated mostly meso- and hyperendemic
villages in Mambasa and lower endemicity in Watsa.4
Sample collection. A convenience sample of 50–100 indi-
viduals ages ³ 14 years old was tested in each village between
21:00 and 01:00 hours to assess filarial antigenemia and Mf
rates; 200 mL finger-prick blood was collected in (ethylene-
dinitrilo)tetraacetic acid (EDTA) -coated tubes.
Antigen and Mf testing. The ICT test for circulating W.
bancrofti antigen (Binax Filariasis Now Card Test; Alere,
Scarborough, ME) was performed according to the manufac-
turer’s instructions and read strictly at 10 minutes after apply-
ing the blood sample. Positive results were documented by
photography (Figure 2). Mf testing was performed using
three-line blood smears (60 mL blood total on the slide) as
previously described.5 Giemsa-stained slides were read at
400 + magnification, and numbers of small/thin (M. perstans)
and large (L. loa orW. bancrofti) Mf were recorded. For each
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slide positive for large Mf, 10 large Mf were examined at
a 1,000 + magnification for differentiation of L. loa and
W. bancrofti. Mf with a single nucleus in the tip of the tail
were identified as L. loa. Slides positive for Mf were sent
to Washington University in St. Louis, MO for reexamina-
tion by microscopy and DNA testing. Some positive and
negative ICT cards were also sent to Washington University
for DNA testing.
Periodicity of L. loa. The periodicity of L. loa Mf was
studied in seven adults (four men and three women; age
range = 28–78 years) in July of 2012. These individuals had
been noted to have high L. loa Mf counts (> 2,000/mL) in
night blood in 2011. Periodicity was assessed by counting
Mf in 60-mL thick smears prepared with blood collected by
finger prick at 05:00, 13:00, and 21:00 hours.
Differentiation of L. loa and W. bancrofti by quantitative
polymerase chain reaction. High Mf densities in many slides
made it impossible to examine all large Mf by microscopy at
1,000 + magnification to exclude the presence ofW. bancrofti
Mf. Therefore, we used probe-based quantitative real-time
polymerase chain reaction (qPCR) assays to detect filarial
DNA. DNA extraction was performed 3–6 months after prep-
aration of the Giemsa-stained blood smears. Sterile razor blades
were used to scrape dried blood from stained blood smears
(two lines; equivalent to 40 mL). DNA was isolated from dried
blood using the QIAamp DNA Extraction Kit for Blood
(QIAGEN, Valencia, CA). Alternatively, DNA was extracted
from dried blood on one-half of an ICT card sample application
pad as previously described.6 Blood samples were tested with
two separate qPCR reactions for detection of W. bancrofti and
L. loa DNA as previously described.6,7 Giemsa-stained slides
from Coˆte d’Ivoire that contained W. bancrofti Mf but no
L. loa Mf were used as positive controls for the W. bancrofti
qPCR assay and negative controls for the L. loa qPCR assay.
Statistics. R 3.0.1 (http://www.r-project.org/)8 was used to
develop the generalized linear model (GLM)9 and design the
map.10,11 A GLM with a binomial function was developed to
identify significant predictors of positive ICT test results. Pre-
dictor variables in this model included age, sex, number of
L. loa Mf per milliliter, and number of M. perstans Mf per
milliliter. Maps were drawn using the R3.0.1 packages Maps
(http://cran.r-project.org/web/packages/maps/index.html) and
Figure 1. Map of (left panel) the study area in the northeastern DRC showing (right panel) the examined villages in the Mambasa and
Watsa Territories.
Figure 2. A shows a weakly positive ICT card test from a subject from the Ituri region with L. loaMf. Note that the test line (T; marked with
an arrow) is the same color as the control (C) line. B shows a Giemsa-stained L. loa Mf in a night blood smear from the same subject. Note the
characteristic elongated nuclei in the tip of the tail (arrow).
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Mapdata (http://cran.r-project.org/web/packages/mapdata/index
.html).10,11 Global positioning system (GPS) coordinates of
the villages were recorded during the study period, and data
detailing the administrative areas were taken from DIVA-GIS
(www.diva-gis.org).
Ethical approval. This mapping was performed as part of
the National Program to Eliminate LF in the DRC. Collec-
tion of blood samples for the periodicity study was approved
by the Ethical Committee of the School of Public Health,
Kinshasa University, DRC.
RESULTS
Prevalence rates for positive ICT tests and Mf. In total,
2,724 individuals were tested in 30 villages in the Ituri and
Haut Uele regions. Overall prevalence rates for filarial
antigenemia and Mf in night blood with large sheathed Mf
were 6% and 22%, respectively (Table 1). Positive ICT tests
were observed in 28 of 30 villages, and 7 villages had ICT
rates of at least 10%. Positive ICT tests had clearly visible
T lines that were the same color as the control or C lines
(Figure 2A). This result distinguishes these test results from
false-positive tests that occur when tests are read well after
the recommended read time of 10 minutes.12
Prevalence rates by village for large sheathed Mf in night
blood ranged between 4% and 40% (Table 1). Geometric
mean Mf densities in infected individuals ranged from village
to village from 92.6 to 567.7 Mf/mL, and some individuals had
Mf counts of > 20,000/mL. The maximum number of large Mf
of 47,448 Mf/mL was detected in an 85-year-old woman who
had lived in Apodo for the last 35 years. She also had
M. perstans (1,549 Mf/mL). Many of the large sheathed Mf
were unambiguously identified as L. loa by morphology
(Figure 2B), and no W. bancrofti Mf were identified.
However, given the high number of large Mf in the slides
(12% of the samples with large Mf had > 120 Mf per 60 mL),
it was impossible to exclude the presence of W. bancrofti Mf
by microscopy alone.
M. perstans Mf are much smaller than Mf of L. loa or
W. bancrofti, and they were easily differentiated by micros-
copy. M. perstans prevalence rates by village ranged from
22% to 98%. Eighteen (60%) of the villages surveyed had
M. perstans Mf prevalence rates of at least 70%. Geometric
mean Mf counts for individuals with M. perstans by village
ranged between 221.6 and 2,605.3 Mf/mL, with a geometric
mean density of 582.3 Mf/mL. This number is more than
two times as high as the mean density of L. loaMf.
Species identification of Mf in night blood by qPCR. qPCR
testing was performed on blood from 337 slides that were pos-
itive for large sheathed Mf by microscopy (Table 2). L. loa
DNA was detected in 294 (87%) samples. Because some blood
samples contained very few Mf and recovery of DNA from
stained smears is incomplete, it is likely that all tested slides
with large Mf contained L. loa DNA. In contrast,W. bancrofti
DNA was detected in only 1 of 337 blood samples tested
(0.3%). This sample was from a 66-year-old woman who had
Table 1
Summary of filarial antigenemia and Mf test results from night blood surveys in the Ituri and Haut Uele regions in the eastern DRC by village
Village name N tested ICT positive (%) Rate of L. loaMf (%) Geometric mean* of L. loa (Mf/mL) Rate ofMpMf (%) Geometric mean* ofMpMf (Mf/mL)
Ituri
Memekidele 71 10 27 160.3 97 2,605.3
Aluta 100 10 19 241.2 98 547.7
KeroZanzibar 90 7 21 168.1 85 877.4
Digbo 77 6 27 325.4 97 2,033.9
Ekwe 100 5 13 342.1 94 1,481.3
Epulu 98 5 17 155.6 44 379.3
Salate 89 4 10 567.7 62 413.4
Saiyo 53 4 19 545.0 83 2,018.0
Nduye 100 3 26 257.8 78 276.7
Komboni 100 3 21 309.5 92 1,194.1
Molokayi 100 3 10 302.2 61 449.9
Malembi 100 2 13 290.1 96 1,048.9
Bapukeli 98 2 19 147.2 70 913.4
Butiaba 2 50 0 16 180.5 86 1,125.5
Haut Uele
Bayitebi 100 14 37 150.3 76 410.5
Obo II 100 13 30 161.3 75 221.6
Kossia 100 12 29 203.4 79 648.6
Obo I 100 10 37 314.1 76 288.1
Luwi 100 10 27 285.6 79 547.8
Apodo 100 8 40 451.2 73 429.7
Netiti-Gombari 100 8 25 278.1 67 562.3
Tibodri 100 8 26 137.8 65 506.9
Bakiri 100 7 35 267.3 59 832.8
Dodi 100 7 14 270.7 91 1,205.5
Andekofu 88 6 20 324.1 61 499.1
Osso I 100 5 24 212.5 63 607.1
Kadungu 87 3 21 109.1 50 351.1
Ngili-ngili 94 2 4 139.9 22 616.8
Andra 76 1 20 113.8 30 1,367.3
Toli 53 0 11 92.6 43 594.9
Total 2,724 6 22 231.2 72 582.3
Large sheathed Mf were identified by morphology as L. loa, whereas small unsheathed Mf were identified asM. perstans (Mp). Mf densities were not available for allMp-positive samples from
some villages.
*The geometric mean number of Mf was calculated for Mf-positive subjects.
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lived in Ekwe village for the past 5 years and also had loiasis.
We do not have information on where she lived before that
time. We also tested sample application pads from 52 positive
and 60 negative ICT cards for the presence of L. loa and W.
bancroftiDNA; 36 of 52 subjects with positive ICT card results
had large sheathed Mf in their thick blood smears, and 33 of
the sample application pads from these ICT cards were positive
for L. loaDNA by qPCR. Blood from the same female patient
mentioned above from Ekwe was positive for DNA of both L.
loa andW. bancrofti, but none of the other 111 card test appli-
cation pads were positive for W. bancrofti DNA; 1 of 16 ICT
positive blood samples from people with blood smears that did
not contain large Mf was positive for L. loa DNA by qPCR.
Also, 10 of 60 ICT negative card tests were from people with
large Mf in night blood smears, and 8 of them were positive for
L. loa DNA by qPCR. The other 50 ICT negative samples had
no large Mf in night blood, and 1 of these samples was positive
for L. loa DNA by qPCR. These results show that (with one
exception) the large Mf present in night blood samples col-
lected in this study were L. loa.
Relationship between ICT card positivity and L. loa Mf
density. ICT card test positivity was clearly linked to the pres-
ence and number of L. loaMf in night blood smears (Table 3).
In total, 131 of 577 (22.7%) blood samples from people with
L. loa Mf had positive ICT tests. Although only 2% of indi-
viduals without L. loa Mf in night blood had positive antigen
tests, almost 60% of those with Mf counts > 2,000/mL had
positive ICT tests; 7 of 15 subjects with Mf counts between
8,000 and 30,000 Mf/mL had positive ICT tests. The only
person with > 30,000 Mf/mL in the night blood was the elderly
woman mentioned above who had a negative ICT test.
The ICT positivity rate for blood samples from persons
who were negative for M. perstans Mf and persons with
low (£ 100 Mf/mL), medium (101–1,999 Mf/mL), or high
M. perstans Mf counts (> 2,000 Mf/mL) ranged between 4%
and 10%. Mf counts between 8,000 and 30,000 Mf/mL were
detected in 65 individuals, and only 8 of these people had
positive ICT test results. Higher M. perstans Mf counts were
observed in only four subjects, and all of these subjects had
negative ICT test results. A GLM comparing the differences
in ICT test results with M. perstans Mf counts found no
relationship between these two variables, whereas high L. loa
Mf counts were strongly associated with positive ICT test
results (Table 4).
Periodicity of L. loa Mf. Periodicity studies were per-
formed because of the unexpected finding that L. loaMf were
commonly seen in night blood. Finger prick blood was col-
lected at 21:00, 05:00, and 13:00 hours from seven people that
had L. loa Mf present in night blood samples during the first
survey in 2011. All of these individuals were coinfected with
M. perstans at that time, with Mf densities between 333 and
8,413 Mf/mL. At the time of reexamination in 2012, one man
was Mf-negative, and the others had night blood L. loa Mf
counts between 608 and 31,728 Mf/mL. Two individuals (sub-
jects 2 and 3) had a diurnally periodic pattern, with almost no
Mf at 21:00 and 05:00 hours but high counts of > 25,000 Mf/
mL at 13:00 hours (Figure 3). Subjects 1 and 5 had diurnally
subperiodic patterns, and two individuals (subjects 6 and 7)
had aperiodic patterns, with > 20,000 Mf/mL at all three
time points. These results show that L. loa exhibits atypical
Table 2
Detection of filarial antigenemia (ICT) and parasite DNA in night
blood samples from subjects with large sheathed Mf in night
blood smears
Village
N tested by qPCR N positive




DNA by qPCRICT positive ICT negative
Ituri
Memekidele 5 15 19 0
Aluta 8 12 18 0
KeroZanzibar 3 16 18 0
Digbo 4 16 12 0
Ekwe 4 9 12 1
Epulu 1 16 14 0
Salate 2 7 8 0
Saiyo 2 8 10 0
Nduye 3 23 23 0
Komboni 4 18 17 0
Molokayi 2 8 9 0
Malembi 3 11 13 0
Bapukeli 1 18 16 0
Butiaba 2 0 8 8 0
Haut Uele
Bayitebi 14 0 13 0
Obo II 13 0 11 0
Kossia 12 0 8 0
Obo I 10 0 9 0
Luwi 10 0 7 0
Apodo 8 3 11 0
Netiti-Gombari 7 0 7 0
Tibodri 6 0 6 0
Bakiri 7 0 7 0
Dodi 7 0 7 0
Andekofu 4 0 4 0
Osso I 5 2 5 0
Kadungu 2 0 2 0
Ngili-ngili 0 0 – –
Andra 0 0 – –
Toli 0 0 – –
Total 147 190 294 1
Table 3
Relation of positive filarial antigen test results (ICT) with L. loa and
M. perstans Mf count
Mf density (Mf/mL)
ICT negative ICT positive ICT invalid
Total NN Percent N Percent N Percent
L. loa
0 2,065 97.59 37 1.75 14 0.66 2,116
1–100 206 91.56 18 8.00 1 0.44 225
101–2,000 240 76.68 72 23.00 1 0.32 313
> 2,000 29 41.43 41 58.57 0 0 70
Total 2,540 93.25 168 6.17 16 0.58 2,724
M. perstans
0 673 95.33 29 4.10 4 0.57 706
1–100 270 94.07 17 5.92 0 0 287
101–2,000 740 90.13 77 9.38 4 0.49 821
> 2,000 282 88.96 33 10.41 2 0.63 317
Total 1,965* 92.21 156* 7.32 10* 0.47 2,131*
Mf were counted on a single 60-mL night blood smear, and counts were converted to Mf
per milliliter.
*M. perstans Mf counts were not available for all M. perstans Mf-positive individuals.
Slides from 593 M. perstans Mf-positive and L. loa Mf-negative subjects from six villages
were not counted.
Table 4
Results from a GLM that assessed associations between filarial antigen
test results and age, sex, and Mf counts for L. loa and M. perstans
Variable Estimate SE Z score P value
Intercept −3.176 1.043 −11.208 < 0.0001
Age 0.174 0.302 2.114 0.0345
Sex (males) 0.697 0.766 0.910 0.363
L. loa (Mf/mL) 0.089 0.066 4.958 < 0.0001
M. perstans (Mf/mL) −0.045 0.036 −1.276 0.202
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periodicity in some subjects in the study area, and many sub-
jects had high Mf counts in night blood.
DISCUSSION
The purpose of this study was to map the distribution of LF
in the Ituri and Haut Uele regions of the DRC before initiation
of MDA for LF elimination. With only 1W. bancrofti infection
identified (by PCR only) from > 2,700 people tested, it is safe
to say that MDA is not required for these regions. This finding
underlines the importance of careful mapping before initiating
MDA for LF in central Africa, where the infection is often
highly focal and historical information on prevalence is spotty.
In contrast to W. bancrofti, infections with L. loa and M.
perstans were highly prevalent in the study areas. The pres-
ence of loiasis was not surprising, because recent rapid assess-
ment of prevalence of Loa loa (RAPLOA) surveys had
documented high rates of loiasis in these regions.13,14 How-
ever, high rates of L. loa Mf in night blood samples in this
study were a major surprise. This result contrasts with the
common assumption that people in central Africa with large
sheathed Mf in night blood have bancroftian filariasis,
whereas those with large sheathed Mf in day blood have
loiasis.2 Periodicity studies showed that L. loa Mf counts did
not exhibit the expected diurnal pattern in some subjects in
the study areas. Additional research is needed to determine
the relative frequency of these atypical periodicity patterns
(diurnal subperiodic and aperiodic) and assess whether par-
ticular genotypes are associated with aperiodic L. loa.
The presence of high numbers of L. loa Mf in night blood
samples has important implications for mapping LF in areas
of central Africa with loiasis. It is not possible to rule out the
presence of W. bancrofti Mf by microscopy when L. loa Mf
counts are high in night blood samples. Although we assumed
that this problem could be avoided by antigen testing, our
results suggest that the ICT test may not be specific for
W. bancrofti infection in loiasis coendemic areas of Africa.
Prior studies have shown that, although the epitope recog-
nized by the monoclonal antibody AD12.1 is present in anti-
gen extracts from many nematode species, filarial antigen
tests, such as the Binax Now Filariasis Test, that use this
antibody (or the closely related Og4C3 monoclonal antibody)
have until now been considered to be specific forW. bancrofti
infection. Prior studies of the Binax Now Filariasis Test have
not detected filarial antigen in serum samples from patients
infected with B. malayi, O. volvulus, M. perstans, or L. loa
(apart from a few samples from people who had also been
exposed to W. bancrofti).15–17 The ICT card test has been
extensively used in areas with onchocerciasis, and no evidence
for cross-reactivity has been observed.18,19 However, rela-
tively few serum or plasma samples from patients with loiasis
were tested in these prior studies, and some of these samples
were from Americans who had acquired the infection as mis-
sionaries or Peace Corps volunteers in Africa. It seems likely
that some people with loiasis in the study area have a circulat-
ing L. loa antigen that is immunologically cross-reactive with
the 200-kDaW. bancrofti adult worm antigen that is detected
by the Binax Now Filariasis ICT Test.16 Because most (77%)
blood samples from subjects with L. loaMf had negative ICT
test results, ICT positivity in loiasis is likely to be associated
with high L. loa adult worm loads. Prior studies have shown
that circulating filarial antigen levels are correlated with adult
female worm counts in dogs infected with Dirofilaria immitis
and jirds infected with B. pahangi.20,21 An association with
adult worm loads would explain the increased frequency of
ICT positivity in subjects with very high night blood Mf
counts and the lack of positivity in prior studies with loiasis
serum from expatriates and Africans from other Loa-endemic
countries. The relatively high frequency of negative ICT tests
in people with Loa Mf counts > 2,000/mL (41%) might be
explained by immune clearance of the putative circulating
L. loa antigen in some subjects.
Figure 3. Periodicity of L. loa Mf in seven patients with L. loa Mf in night blood smears. One subject (subject 4) had no Mf at the time of
reexamination. The others had variable periodicity patterns that were diurnal (subjects 2 and 3), diurnally subperiodic (subject 5), and aperiodic
(subjects 6 and 7); 60-mL finger prick blood samples were collected at (a) 21:00, (b) 05:00, and (c) 13:00 hours, and Mf densities were determined by
microscopy. The species identification was confirmed to be L. loa in all cases by qPCR.
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Because day blood Mf counts were not performed in this
study, we do not know whether the ICT test might be useful in
areas without LF for detecting persons with very high L. loa
Mf counts (> 30,000/mL) who have an increased risk of devel-
oping neurological severe adverse events after ivermectin.22
Additional studies are needed (with day blood testing in areas
with high rates of loiasis) to answer this question.
The specificity problem that we observed with the ICT card
test in central Africa may be even worse with the Alere Fila-
riasis Test Strip, which also uses the AD12.1 monoclonal anti-
body, because the Test Strip is more sensitive than the ICT
card test.15 It has to be stressed that positive ICT results
caused by cross-reactivity of a Loa antigen are true-positive
results that can be confirmed by retesting. These results are
different from false-positive ICT tests caused by improper
reading of the diagnostic device that are not confirmed when
tests are read correctly after 10 minutes. This finding leads to
the question of how best to map and monitor LF in areas with
high rates of loiasis. Traditional night blood Mf testing might
be sufficient for this purpose in areas where L. loa Mf have
strictly diurnal periodicity. Antibody testing with the recom-
binant filarial antigen Wb-123 could be helpful, but there is no
commercially available version of the test at this time.23 Sim-
ilar to the situation with the ICT test, the specificity of Wb-
123 antibodies for W. bancrofti infection has not yet been
thoroughly evaluated with serum or plasma samples from
Loa-endemic areas in central Africa. For now, we think that
the best option for mapping LF in Loa-endemic regions
would be to test night blood samples for W. bancrofti DNA
by qPCR.24 Dried blood samples can be pooled to reduce
costs, and night blood surveys should be powered to provide
high confidence for detectingW. bancrofti infection rates that
exceed 1% in implementation units, because that is the trip
point for initiating MDA. Several reference laboratories in
Africa have experience with qPCR testing for LF.
In conclusion, this study did not detect a significant pres-
ence of LF in Mambasa or Watsa Territories, and MDA is not
required for that infection in these areas. However, the study
identified factors that will complicate mapping and monitor-
ing activities for LF elimination programs in areas of central
Africa that are highly endemic for loiasis. They include high
rates of L. loa Mf in night blood samples that interfere with
detection of W. bancrofti Mf by microscopy and the unex-
pected finding that some subjects with high-intensity L. loa
infections have positive filarial antigen tests. LF elimination
programs in areas of central Africa with high rates of loiasis
may need to use alternative diagnostic tools, such as antibody
tests or qPCR, for mapping, monitoring, and evaluation.
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